tuneTypical Dose
Most human trials use about 450 to 1000 mg daily for 6 to 12 weeks
Flavonoid
Hesperidin
Hesperidin
Evidence TierCWADA NOT PROHIBITED
watchEffect Window
Any lipid or biomarker effects tend to emerge over weeks rather than days.
check_circleCompliance
WADA NOT PROHIBITED
Overview
Clinical Summary
Hesperidin may modestly improve some lipid markers in adults, but evidence for blood-pressure, endothelial, or broad anti-inflammatory benefits remains inconsistent and formulation dependent.
Hesperidin is a citrus flavonoid with a real but limited human evidence base. The best current meta-analyses suggest modest improvements in LDL cholesterol, total cholesterol, and triglycerides. Blood-pressure effects are inconsistent, and endothelial or anti-inflammatory findings are mostly biomarker-level, exploratory, and formulation dependent. That makes hesperidin a cautious cardiometabolic adjunct, not a dependable vascular-performance supplement.
Hesperidin is a citrus flavonoid usually discussed in relation to endothelial signaling, oxidative stress, and lipid metabolism. Those mechanisms are plausible, but the human evidence is stronger for modest lipid effects than for broad vascular or anti-inflammatory claims.
Outcomes
What This Is Expected To Influence
Primary Outcomes
- Modest improvement in LDL cholesterol, total cholesterol, and triglycerides
Secondary Outcomes
- Inconsistent blood-pressure effects
- Weak biomarker-level support for endothelial or inflammatory improvement
Safety
Contraindications and Interactions
Contraindications
- Using it in place of lipid or blood-pressure treatment
Side effects
- Mild GI upset
Interactions
- Antihypertensive medications
Avoid if
- You are expecting drug-like blood-pressure lowering
- You cannot verify the formulation and dose
Evidence
Study-level References
hes-SRC-001Systematic review and meta-analysis
Sourceopen_in_newShylaja H, Viswanatha GL, Sunil V, Hussain SM, Farhana SA. Effect of hesperidin on blood pressure and lipid profile: A systematic review and meta-analysis of randomized controlled trials. Phytother Res. 2024;38(5):2560-2571. doi:10.1002/ptr.8174. PMID:38462779.
Population: Healthy and diseased adults from randomized controlled trials evaluating hesperidin against placebo or control.
Dose protocol: Approximately 292 to 1000 mg daily across randomized trials
Key findings: Reduced LDL cholesterol, total cholesterol, and triglycerides, with no convincing pooled blood-pressure effect.
Notes: Best current overview for the supplement’s practical framing.
Paper content
This is the best current high-level anchor for hesperidin’s cardiometabolic framing. The pooled evidence supports modest lipid improvements, particularly LDL, total cholesterol, and triglycerides, but it does not show a convincing overall blood-pressure effect. That means hesperidin is better framed as a low-confidence adjunctive lipid-support flavonoid than as a reliable antihypertensive supplement.
hes-SRC-002Randomized controlled trial
Sourceopen_in_newSalden BN, Troost FJ, de Groot E, Stevens YR, Garcés-Rimón M, Possemiers S, Winkens B, Masclee AAM. Randomized clinical trial on the efficacy of hesperidin 2S on validated cardiovascular biomarkers in healthy overweight individuals. Am J Clin Nutr. 2016;104(6):1523-1533. doi:10.3945/ajcn.116.136960. PMID:27797708.
Population: Healthy overweight and obese adults.
Dose protocol: Hesperidin 2S 450 mg daily for 6 weeks
Key findings: No overall endothelial-function improvement, with only exploratory subgroup benefits.
Notes: Useful RCT showing why vascular claims should stay narrow.
Paper content
This is a useful reality check for hesperidin. A specialized 2S preparation did not improve endothelial function in the overall trial population, although exploratory subgroup analyses looked more favorable. That supports cautious biomarker framing and argues against overselling hesperidin as a dependable endothelial supplement.
hes-SRC-003Systematic review and meta-analysis
Sourceopen_in_newLorzadeh E, Ramezani-Jolfaie N, Mohammadi M, Khoshbakht Y, Salehi-Abargouei A. The effect of hesperidin supplementation on inflammatory markers in human adults: A systematic review and meta-analysis of randomized controlled clinical trials. Chem Biol Interact. 2019;307:8-15. doi:10.1016/j.cbi.2019.04.016. PMID:30991044.
Population: Human adults enrolled in randomized controlled trials of hesperidin supplementation.
Dose protocol: Trial specific hesperidin protocols across 6 RCTs
Key findings: Improved VCAM-1 but not most other inflammatory markers.
Notes: Supports only narrow biomarker-level anti-inflammatory framing.
Paper content
This review supports only narrow biomarker-level anti-inflammatory framing. Hesperidin improved VCAM-1, while most other inflammatory markers did not change clearly. That makes “anti-inflammatory” too broad as a consumer-facing claim unless the uncertainty is stated directly.